jaybe

@5_utr You can’t spell claudin without claud…

Once we can use next generation AI to allow for tumor-informed ctDNA and gut microbiota adjustment to select for biomarker-enriched next-frontier actionable mutations for a scalable solid tumor strategy, genuine Precision Oncology will be finally achieved! Bingo!

AI concludes "retirement is the leading cause of death"...

@CEOCorbus @bradloncar How to assign weights to inputs and connections that are unknown? Biology is not rational, it does not compute. Basic research must define parameters for ML to succeed. AI will disseminate state of the art, expediting hypothesis, but not conclusions.

I agree it can probably do 90% of the type of science that is routinely published in journals. Maybe even 98%. But no one will remember that science. It's either repetitive, minutely incremental or fraudulent. It's the big leap stuff that makes a real dent. The creative bit with AI I am not convinced about. It's amazing at mimicking and there is real vale to that. TBD i guess.

The Block layoff news was a big deal yesterday. I’m sorry to say that ML driven automated labs are going to do the same to lab jobs in life sciences that AI is starting to do to other industries.

@5_utr The TP53 Y220C mutation occurs in approximately 1% of all solid tumors...

surgery out here deleting tumors at the filesystem level. radiation running rm -rf on mutant and wild-type alike. your precision drug needs Y220C, a full moon, and $18k/month for 20% ORR 😅 necessary? no. sufficient? also no. Biotech valuation-maxxing, response-minning 🗑️

@sharkbiotech Best calculator I know for this… nytimes.com/interactive/20…

my single daughter looked at a house she figured she would invest her savings and pay the mortgage with the rent then I did the math with her doesnt work she would amost break even mortgage vs rent , but taxes insurance maintenance makes it untenable

I taste greatness! This is my #PepsiEntry for a chance to win $5K playing the @Pepsi #PepsiTasteWins jackpot! Tap below and post to enter to win yourself! U.S. res, 18+. Ends 2/8/26, 9:45pm ET. Rules: bit.ly/4sPVh5F

@jesse_brodkin @JacobPlieth @ApexOnco Combo in the morning vs. pembro at night? Easy win.

@JacobPlieth @ApexOnco oh boy a combo study with Keytruda... how innovative 🥱

$EIKN prices at $18/share, to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: oncologypipeline.com/apexonco/node/…

Art is a conversation between a set of intentions and the unintended consequences of making it. Art begins at the 2nd prompt...

@JacobPlieth honorary...

So for some reason I've got my blue tick back. This is bizarre, as I've never paid Elon any money. Some kind of glitch?

@torpedoswap Pre-trial conference set for Jan 9...2026.

$BMYRT update - the court has denied most of BMS motion to dismiss the 2nd complaint. This essentially means the 2nd lawsuit is now live and moving forward. It will be 5 years!

@WallStSai 67

$BMY Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules Bristol Myers accused of delaying FDA approvals for three drugs Lawsuit linked to $80.3 billion Celgene acquisition reuters.com/world/bristol-…

$MGNX Who remembers MGC006 from 2014? Up to MGC030 now, and only one approval for 'Marge'...subsequently de-commercialised.

$MRSN Why mersana@argotpartners.com? Because loose lips sink ships…

Think we will see a record number of deals at #jpm26...

@raffcolo @JacobPlieth @jq1234t Dolasythen?

@JacobPlieth @jq1234t Interesting that they specifically call out "free payload and major metabolite"!

There's some reason why $JNJ doesn't want you to know about its anti-ENPP3 ADC. Via @ApexOnco -> oncologypipeline.com/apexonco/node/… $XNCR

@bioinvestor24 Looks promising, but what percent of PDAC is both MTAPdel and G12Dm? 20%?

$TNGX PRMT5 inh and $RVMD pan RAS inh show mutually exclusive mechanisms ( at least on paper ) one at the chromatin level and the other at cytoplasmic membrane ( for simplicity ). Also non overlapping toxicity ( no report of skin toxicity with TNG 462). Although animal studies to be taken with caution , but this synergy below is remarkable .. easily seen as dominating front line pancreatic and potentially other cancers. ( in lung ca , rate of double RAS mutation and MTAP deletion is higher than ALK pos tumors. Look at some ALK companies silly valuation $NUVL)

@NotthatkindofDr @GermanBiotech Download ‘AACR Meetings’ app, search for ‘ZW191’

@GermanBiotech Is the abstract published somewhere? Not attending the conference this year but don’t see it posted 🙏

It will be exciting to see whether $ZYME has succeeded in validating its ADC technology for the first time. The launch of a webcast reflects a certain optimism on the part of the company. ir.zymeworks.com/news-releases/…

@adamfeuerstein True, but where did you pahk yuh cah?

This view does not suck. #STATSummit

@Mykalt45 @CrossBridgeBio Somewhere between $0 and $500M, depending on who you (get to) present the ppt to…

What’s a next generation ADC company with their own linker and built for dual payloads that will be in the clinic next year worth?! @CrossBridgeBio

@bioinvestor24 @houndcl It looks like a peptide wearing a scary Halloween costume.

@houndcl Are the macrocyclic peptides more difficult to manufacture in bulks ?